Table 5  Therapeutic strategies for COVID-19 and outcomes
Study population  Results
Patients, n  57
Medications, n (%)
Steroids (for COVID-19)  19 (35)
Antibiotics  35 (63)
 Azitromycin  15 (27)
 >1 antibiotic  16 (29)
Antivirals  5 (9)
 Lopinavir/ritonavir  3 (5)
 Darunavir/cobicistat  1 (2)
 Remdesivir  1 (2)
Immunomodulator  3 (5)
 Tocilizumab  1 (2)
 Rituximab  1 (2)
 Ruxolitinib  1 (2)
Hydroxychloroquine  24 (44)
Oxygen therapy (higher intensity), n (%)
Overall  30 (54)
 Nasal cannula  18 (32)
 Non-invasive ventilation  8 (14)
 Invasive mechanical ventilation  4 (7)
Outcomes, n (%)
Death  7 (12)
ARDS  11 (19)
ICU admission  4 (7)
Hospitalisation (no ICU)  37 (65)
 Need for rehabilitation  7 (17)
Duration of hospitalisation, median (IQR)
Hospital stay  10 (7–22)
 ICU stay  16 (10–19)
Rehab stay  14 (11–15)
ARDS, acute respiratory distress syndrome; ICU, intensive care unit.